Cancer drug repurposed to fight rare, recurring joint tumor
NCT ID NCT01207492
Summary
This study tested whether nilotinib, a drug used for leukemia, could help control a rare, non-cancerous joint tumor called pigmented villonodular synovitis (PVNS) when it comes back or spreads. Seventeen adults with recurrent or metastatic PVNS took nilotinib pills twice daily. The main goal was to see if the drug could stop the tumor from growing for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.